- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- Market Cap
- $146.52M
- Enterprise Value
- $115.85M
- EPS (TTM)
- -CN¥0.50
- EBITDA (TTM)
- -CN¥88.34M
- Year Range
- $1.46 - $6.79
- Target Price
- $9.00
- ROA (TTM)
- -17.76%
- ROE (TTM)
- -20.03%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NBP Performance Chart
NovaBridge Biosciences (NBP) is down 61.6% since the beginning of the year. At $2 per share, NBP is trading 77.5% below its 52-week high of $7. Investors who bought $1,000 worth of NBP shares 5 years ago would now be looking at an investment worth $19.
Loading charts...
Returns By Period
NovaBridge Biosciences (NBP) has returned -61.56% so far this year and -38.80% over the past 12 months.
NovaBridge Biosciences
- 1D
- 2.00%
- 1M
- -13.56%
- YTD
- -61.56%
- 6M
- -65.15%
- 1Y
- -38.80%
- 3Y*
- -20.54%
- 5Y*
- -54.56%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
NBP Monthly Returns History
Based on dividend-adjusted daily data since Jan 17, 2020, NBP's average daily return is +0.03%, while the average monthly return is -0.06%.
Historically, 44% of months were positive and 56% were negative. The best month was Aug 2025 with a return of +107.0%, while the worst month was Jan 2022 at -46.7%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.
On a daily basis, NBP closed higher 45% of trading days. The best single day was Jun 3, 2025 with a return of +46.1%, while the worst single day was Jun 26, 2025 at -27.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.83% | -0.91% | -25.00% | 0.41% | -25.51% | -16.85% | -61.56% | ||||||
| 2025 | 20.00% | -9.22% | -11.03% | 14.09% | 39.36% | 84.73% | -16.94% | 106.97% | -9.13% | 30.95% | -22.42% | 3.65% | 368.24% |
| 2024 | -6.84% | 0.56% | 4.49% | -4.84% | -6.21% | 0.60% | -16.77% | -18.71% | 9.73% | -13.71% | -12.90% | -8.80% | -55.26% |
| 2023 | 44.02% | -28.57% | -19.53% | -10.98% | 0.65% | -3.55% | -3.68% | -34.03% | -30.53% | 8.33% | 9.09% | 21.79% | -54.55% |
| 2022 | -46.72% | -2.10% | -34.30% | -22.78% | -30.62% | 29.89% | -7.26% | -41.51% | -34.58% | -7.48% | -0.27% | 12.97% | -91.18% |
| 2021 | 15.36% | 8.83% | -18.11% | 26.08% | 32.66% | 3.55% | -6.99% | -9.17% | 2.21% | -14.76% | -2.15% | -21.62% | 0.51% |
Benchmark Metrics
NovaBridge Biosciences has an annualized alpha of -6.29%, beta of 0.89, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since January 17, 2020.
- This stock participated in 189.15% of S&P 500 Index downside but only 44.12% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -6.29%
- Beta
- 0.89
- R²
- 0.04
- Upside Capture
- 44.12%
- Downside Capture
- 189.15%
Return for Risk
Risk / Return Rank
NBP ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for NovaBridge Biosciences (NBP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.41 | ||
| Sortino ratioReturn per unit of downside risk | -2.71 | ||
| Omega ratioGain probability vs. loss probability | 1.01 | 1.37 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | -0.50 | 2.78 | -3.29 |
| Martin ratioReturn relative to average drawdown | -0.86 | 12.44 | -13.30 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NovaBridge Biosciences. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NovaBridge Biosciences was 99.27%, occurring on Apr 7, 2025. The portfolio has not yet recovered.
The current NovaBridge Biosciences drawdown is 98.19%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.27%Apr 2025 | 3y 9mo | — | 4y 11moJul 2021 - now |
COVID crash2020 | -30.84%Feb 2020 | 26d | 2mo 9d | 3mo 5dJan 2020 - Apr 2020 |
2021 bear market2021 | -30.62%Mar 2021 | 27d | 28d | 1mo 25dMar 2021 - Apr 2021 |
2020 bear market2020 | -29.96%Nov 2020 | 1mo 9d | 1mo 22d | 3mo 1dOct 2020 - Dec 2020 |
2020 correction2020 | -18.59%May 2020 | 2d | 24d | 26dMay 2020 - Jun 2020 |
Drawdown Indicators
| NBP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.27% | -56.78% | -42.49% |
Max Drawdown (1Y)Largest decline over 1 year | -77.59% | -9.10% | -68.49% |
Max Drawdown (3Y)Largest decline over 3 years | -80.06% | -18.90% | -61.16% |
Max Drawdown (5Y)Largest decline over 5 years | -99.27% | -25.43% | -73.84% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.19% | -1.80% | -96.39% |
Average DrawdownAverage peak-to-trough decline | -69.87% | -10.71% | -59.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 44.94% | 2.03% | +42.91% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NovaBridge Biosciences over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NovaBridge Biosciences is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NBP in comparison with other companies in the Biotechnology industry. Currently, NBP has a P/B value of 4.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NBP
Add NovaBridge Biosciences to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NBP